^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Neo Vax (NEO-PV-01)

    i
    Other names: NEO-PV-01, NEO-PV 01, neoantigen-based personalized cancer vaccine
    Associations

    News

    Trials
    Company:
    BioNTech
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    13d
    A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. (clinicaltrials.gov)
    P1, N=15, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2028 --> Jul 2028
    Trial completion date
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Neo Vax (NEO-PV-01)
    1m
    Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor
    |
    Neo Vax (NEO-PV-01)
    1m
    Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, West China Hospital
    New P1 trial • Pan tumor
    |
    Neo Vax (NEO-PV-01)
    2ms
    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    Keytruda (pembrolizumab) • temozolomide • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)
    3ms
    NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | N=30 --> 10 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Mobista (CDX-301) • Neo Vax (NEO-PV-01)
    3ms
    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=56, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    Keytruda (pembrolizumab) • temozolomide • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)
    10ms
    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=56, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jun 2026 --> Feb 2027 | Trial primary completion date: Jun 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    Keytruda (pembrolizumab) • temozolomide • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)
    1year
    A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. (clinicaltrials.gov)
    P1, N=15, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Mar 2026 --> May 2027
    Trial primary completion date
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Neo Vax (NEO-PV-01)
    1year
    Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Feb 2024 --> Dec 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • Neo Vax (NEO-PV-01)
    over1year
    NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jan 2027 --> Sep 2030 | Trial primary completion date: Jan 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Mobista (CDX-301) • Neo Vax (NEO-PV-01)
    over1year
    Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Dana-Farber Cancer Institute | N=20 --> 11
    Enrollment change • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Neo Vax (NEO-PV-01)
    over1year
    NeoVax Plus Ipilimumab in Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Patrick Ott, MD, PhD | Trial completion date: Sep 2026 --> May 2030
    Trial completion date
    |
    Yervoy (ipilimumab) • Neo Vax (NEO-PV-01)